Convergence to Investigate Safety of CNV2197944
CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, for the treatment of chronic pain. It is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis.
The study is expected to conclude in the second quarter of 2012.
The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.
Clive Dix, CEO of Convergence Pharmaceuticals, said: â€œWe are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain. The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain.â€
According to the company, the pain therapeutic area encompasses any disease where pain is a major symptom. The unmet medical need for patients in pain is enormous, with the greatest need being for a more effective therapy that is well tolerated and safe over a long period of time.
Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions.
According to recent research the global pain management market is to reach $60 billion by 2015.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.